News

IV Ibandronate Found to Boost Bone Density as Well as Daily Oral Dosing


 

BOSTON — Intermittent intravenous ibandronate is at least as effective as daily oral ibandronate for increasing bone mineral density and may be preferable to oral dosing in patients with esophageal disease or compliance problems.

There are no fracture data for the intravenous dosing schedule, but the risk reduction that has been shown with oral ibandronate can probably be extrapolated to the intravenous form of the drug, Dr. Mone Zaidi said at the annual meeting of the Endocrine Society.

Oral ibandronate has been shown to reduce the risk of new vertebral fractures by up to 60% (Curr. Med. Res. Opin. 2005;21:391–401; J. Bone Miner. Res. 2004;19:1241–9).

“If you can show equivalence or superiority in bone mineral density changes to [the form] with proven fracture data, which we have done, I think everyone would agree that you can extrapolate that data,” said Dr. Zaidi, director of the Mount Sinai Bone Program, Mount Sinai School of Medicine, New York.

Dr. Zaidi presented 2-year bone mineral density (BMD) data from the ibandronate Dosing Intravenous Administration trial, a Roche-sponsored phase III study that compared two doses of intravenous ibandronate (2 mg every 2 months and 3 mg every 3 months) with the approved oral dosing schedule (2.5 mg daily). The study group included 1,400 postmenopausal women with low bone mass (T-scores of −3.3 for total spine and −2 for hip).

After 2 years, BMD at the lumbar spine increased significantly more in both intravenous groups than in the oral group (mean increase 6.4% for the 2 mg IV dose, 6.3% for the 3 mg IV dose, and 4.8% for the oral dose).

BMD increased similarly at all other sites measured, with consistently greater gains in both intravenous groups than in the oral group, Dr. Zaidi said.

At 2 years, the incidence of adverse events was similar across all groups. Flulike illnesses and gastrointestinal intolerance were seen primarily in the first year, with only slight increases in cumulative numbers during the second year.

There was no osteonecrosis of the jaw. Renal and urinary incidents were uncommon and similar across groups.

Fracture incident, which was reported as an adverse event, was low and similar in all groups, although Dr. Zaidi stressed that the study was not powered to prove fracture risk reduction.

The intermittent dosing would also be “a great way” to ensure compliance, according to Dr. Zaidi.

Recommended Reading

Low Vitamin D and Breast Cancer: Is There a Link? : Consider vitamin D supplements in postmenopausal women being treated with aromatase inhibitors.
MDedge Rheumatology
Inflammatory Diseases Raise Fracture Risk
MDedge Rheumatology
Data Watch: Osteoporotic Fracture–Associated Costs Expected to Rise by 49%
MDedge Rheumatology
Absorption Similar for Nasal, Injected Teriparatide
MDedge Rheumatology
Island Study to Research Genes, Osteoporosis Link
MDedge Rheumatology
Jaw Osteonecrosis Occurred in 1% of Cancer Patients on IV Bisphosphonate
MDedge Rheumatology
Osteoporosis Treatment Guidance Changing
MDedge Rheumatology
'Green' Alternatives Posed for Preserving BMD
MDedge Rheumatology
Raloxifene Has Breast Ca Benefits but Stroke Risks
MDedge Rheumatology
Growth Hormone Tx Often Needed Into Mid-20s, Study Finds
MDedge Rheumatology